From pig kidney transplants to the development of a new schizophrenia drug, here are five of the biggest medical ...

Bristol Myers on Monday said the two Phase 3 studies met their primary endpoint, with a significantly greater proportion of Sotyktu-treated patients achieving at least a 20% improvement in signs and ...

Bristol-Myers Squibb BMY has been added to JP Morgan's Analyst Focus List due to the strong potential of its schizophrenia ...

Last year around this time, several leading drugmakers announced significant M&A deals to help fill their pipelines, including Bristol-Myers Squibb's ( BMY) proposed takeovers of Karuna and RayzeBio, ...

This year saw lofty highs and devastating lows for neuroscience drug developers like Bristol Myers Squibb, Eli Lilly and ...

Oncologists want definitive guidance on whether patients with resectable NSCLC benefit from immunotherapy before and after ...

Look no further than our top two stories of the year, and you’ll see that the GLP-1 craze and Big Pharma layoffs took center ...

The year kicked off with a flurry of dealmaking at the J.P. Morgan Healthcare Conference in January, and the pace of news ...

Health Enterprise Partners ("HEP"), a healthcare private equity firm, is pleased to announce the promotion of David Rauber to Vice ...

Castle Biosciences, Inc. , a company improving health through innovative tests that guide patient care, today provided an update on its test currently in development for use in patients diagnosed with ...

This year’s list features quite a bit of horror mixed in with the usual blockbuster fare—plus smaller hidden gems.

Looking for broad exposure to the Healthcare - Pharma segment of the equity market? You should consider the iShares U.S. Pharmaceuticals ETF (IHE), a passively managed exchange traded fund launched on ...